솔리드 바이오사이언스 (SLDB) 주가 전망: 목표주가, 배당, 최신 뉴스

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.

In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. ; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S. p.

A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences Inc.는 미국에서 신경근육 및 심장 질환 치료제를 개발하는 바이오기업입니다.

주력 후보물질은 SGT-003로 Duchenne muscular dystrophy 치료를 위해 현재 1/2상에 있습니다. 이외에도 SGT-212는 Friedreich's ataxia 치료를 위해 1b상에 있고, SGT-501은 catecholaminergic polymorphic ventricular tachycardia 치료를 위해 전임상 단계에 있으며, SGT-601은 TNNT2 매개 확장성 심근병증 치료제, SGT-401은 BAG3 매개 확장성 심근병증 치료제 모두 전임상 단계에 있습니다. SGT-701은 RBM20 유전자 변이가 특징인 희귀 유전질환 치료용으로 discovery 단계에 있으며, 이 밖에도 심장 및 기타 질환 치료제를 개발하고 있습니다.

또한 capsid libraries, 프로모터·UTRs·인트론 같은 genetic regulators, immunomodulation technologies, manufacturing purity, 그리고 여러 전사체를 하나의 캡시드에 담는 기술인 dual gene expression 등 플랫폼 기술 개발에도 관여하고 있습니다. Ultragenyx Pharmaceutical Inc.와의 협력 및 라이선스 계약과 University of Washington, University of Missouri, University of Florida, ICS Maugeri S.p.A.와의 라이선스 계약을 보유하고 있으며, 2013년에 설립되어 본사는 매사추세츠주 Charlestown에 있습니다.

• 주소: 500 Rutherford Avenue, Third Floor, Charlestown, MA 02129, United States

• 전화번호: 617 337 4680

• 웹사이트: https://www.solidbio.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 121